The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma
Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital Regensburg, 93053 Regensburg, Germany
Center for Neuropathology and Prion Research, Ludwig Maximilians University of Munich, 81377 Munich, Germany
Molecular Neurosciences, Department of Psychiatry and Psychotherapy, University of Regensburg, 93053 Regensburg, Germany
Department of Neuropathology, Regensburg University Hospital, 93053 Regensburg, Germany
Department of Nuclear Medicine, Ludwig-Maximilians-University Munich, 81377 Munich, Germany
Regensburg Center for Interventional Immunology (RCI) and Department Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany
Author to whom correspondence should be addressed.
Received: 14 September 2020 / Revised: 9 October 2020 / Accepted: 9 October 2020 / Published: 14 October 2020
The translocator protein (TSPO) has been under extensive investigation as a specific marker in positron emission tomography (PET) to visualize brain lesions following injury or disease. In recent years, TSPO is increasingly appreciated as a potential novel therapeutic target in cancer. In Glioblastoma (GBM), the most malignant primary brain tumor, TSPO expression levels are strongly elevated and scientific evidence accumulates, hinting at a pivotal role of TSPO in tumorigenesis and glioma progression. The aim of this review is to summarize the current literature on TSPO with respect to its role both in diagnostics and especially with regard to the critical hallmarks of cancer postulated by Hanahan and Weinberg. Overall, our review contributes to a better understanding of the functional significance of TSPO in Glioblastoma and draws attention to TSPO as a potential modulator of treatment response and thus an important factor that may influence the clinical outcome of GBM.